郭宗儒. 化合物效率与先导物优化J. 药学学报, 2013,48(12): 1755-1762.
引用本文: 郭宗儒. 化合物效率与先导物优化J. 药学学报, 2013,48(12): 1755-1762.
GUO Zong-ru. Ligand efficiency and lead optimizationJ. Acta Pharmaceutica Sinica, 2013,48(12): 1755-1762.
Citation: GUO Zong-ru. Ligand efficiency and lead optimizationJ. Acta Pharmaceutica Sinica, 2013,48(12): 1755-1762.

化合物效率与先导物优化

Ligand efficiency and lead optimization

  • 摘要: 活性和成药性是药物的两大支柱,分别是由分子的微观结构与宏观性质所决定。结构的优化是在多维度空间中进行的多参数分子操作。由体外活性过渡到体内的药理效应有许多不确定性,需要在早期优化阶段用分子的多维度规(metrics)评价化合物的质量或效率。本文在讨论表征化合物活性和成药性参数的基础上,阐述调整微观结构中药物-受体结合热力学的焓与熵、结合动力学的离解速率对提高化合物效率的影响,说明优化微观结构对成药性的重要意义。

     

    Abstract: Pharmacological activity and druggability are two pivotal factors in drug innovation, which are respectively determined by the microscopic structure and macroscopic property of a molecule. Since structural optimization consists in a molecular operation in the space with multi-dimensions, and there exists a body of uncertainties for transduction from in vitro activity into in vivo pharmacological response. It is necessary for early stage in lead optimization to evaluate compound quality or efficiency using a kind of metrics containing multi-parameters. On the basis of the describing parameters of activity and druggability, this overview deals with the roles of thermodynamic signatures and binding kinetics of drug-receptor interactions in optimizing quality of compounds, signifying the significance in optimization of microscopic structures for drug discovery.

     

/

返回文章
返回